Loading color scheme

Virtici
  • Home
  • About us
  • Focus
  • Ecosystem
  • Leadership
  • News
  • Careers
  • Contact Us

Changing lives through

innovation

learn more

SNAPSHOT

Building a track record of success

+
active product programs
M+
invested in innovation & product development
Research Sites
startups
revenue- driving agreements

What We Do

Virtici provides the leadership, space and funding support to transform innovations into products...

VALUE CREATION

  • 1 Select

  • 2 Innovate

  • 3 Develop

learn more

Virtici leadership brings decades of experience  
that intersect innovation and product development.

Meet the team

Virtici Ecosystem

Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients.

 

Areas Of Innovation

Virtici is actively seeking the most innovative product and
platform concepts in the following disease areas.

  • Oncology

  • Microbiome

  • Neurology

  • Autoimmunity

  • Inflammation

  • Infectious Disease


learn more

 

The ASCEND Hub is a Regional Technology Accelerator Hub for the seven Western States: Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. The NIH funded program empowers innovators to accelerate biomedical commercialization through entrepreneurial education, mentorship, and technology development funding.

learn more

Latest News

Jan 31, 2023

Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis

Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

Read more
Nov 14, 2022

Celdara Medical Receives Funding to Develop Broad-Spectrum Antimicrobials for Chronic Lung Infection

Lebanon, NH: The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded Celdara Medical, LLC a Phase I Small Business Innovation Research (SBIR) grant for development of broad-spectrum antimicrobial peptides to combat chronic lung infection in patients with cystic fibrosis (CF).

Read more
Oct 05, 2022

Virtici Announces Funding from NIH to Develop a New Treatment for Periodontal Disease

Seattle, Washington - Virtici LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) award to advance VTC-886, a first-in-class small molecule for the prevention of P. gingivalis infection.

Read more
Jan 21, 2022

Rise Therapeutics Begins Operations of its GMP Manufacturing Facility

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Read more
Jan 17, 2022

Aclys Bio and Genmab Enter Research and Commercial License Option Agreement to Develop Proprietary Aclys Antibodies Against an Undisclosed Target

Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Read more
Sep 01, 2021

Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.

Read more

  • 464 12th Ave, Ste 400
  • Seattle, WA 98122-5567
  • E: info@virtici.com
© 2023. All Rights Reserved. Privacy Policy
  • Home
  • About us
  • Focus
  • Ecosystem
  • Leadership
  • News
  • Careers
  • Contact Us